Contact
Please use this form to send email to PR contact of this press release:
TCR² Therapeutics Announces RECIST Responses with First TC-210 Dose Tested in Advanced Mesothelin-Expressing Solid Tumors
TO:
Please use this form to send email to PR contact of this press release:
TCR² Therapeutics Announces RECIST Responses with First TC-210 Dose Tested in Advanced Mesothelin-Expressing Solid Tumors
TO: